| Literature DB >> 29027004 |
Raquel Alenda1,2, Lucienne Costa-Frossard3,2, Roberto Alvarez-Lafuente4,2, Carmen Espejo5,6,2, Eulalia Rodríguez-Martín1,2, Susana Sainz de la Maza3,2, Noelia Villarrubia1,2, Jordi Río5,6,2, María I Domínguez-Mozo4,2, Xavier Montalban5,6,2, José C Álvarez-Cermeño3,2, Luisa M Villar7,8.
Abstract
Response to interferon-beta (IFN-beta) treatment is heterogeneous in multiple sclerosis (MS). We aimed to search for biomarkers predicting no evidence of disease activity (NEDA) status upon IFN-beta treatment in MS. 119 patients with relapsing-remitting MS (RRMS) initiating IFN-beta treatment were included in the study, and followed prospectively for 2 years. Neutralizing antibodies (NAb) were explored in serum samples obtained after 6 and 12 months of IFN-beta treatment. Soluble cytokines and blood lymphocytes were studied in basal samples by ELISA and flow cytometry, respectively. 9% of patients developed NAb. These antibodies were more frequent in patients receiving IFN-beta 1b than in those treated subcutaneous (p = 0.008) or intramuscular (p < 0.0001) IFN-beta 1a. No patient showing NAb remained NEDA during follow-up. Basal immunological variables are also associated with patient response. Percentages below 3% of CD19 + CD5 + cells (AUC 0.74, CI 0.63-0.84; OR 10.68, CI 3.55-32.15, p < 0.0001; Likelihood ratio 4.28) or above 2.6% of CD8 + perforin + T cells (AUC 0.79, CI 0.63-0.96; OR 6.11, CI 2.0-18.6, p = 0.0009; Likelihood ratio 5.47) increased the probability of achieving NEDA status during treatment. Basal blood immune cell subsets contribute to identify MS patients with a high probability of showing an optimal response to IFN-beta.Entities:
Keywords: Biomarkers; Demyelinating diseases; Lymphocytes; Multiple sclerosis
Mesh：
Substances：
Year: 2017 PMID： 29027004 DOI： 10.1007/s00415-017-8625-6
Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849